Get the Stockscreener App
1.35
0.75%
0.01
VolitionRX Ltd stock is traded at $1.35, with a volume of 392.73K.
It is up +0.75% in the last 24 hours and down -2.88% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$1.34
Open:
$1.36
24h Volume:
392.73K
Relative Volume:
1.41
Market Cap:
$16.09M
Revenue:
$2.47M
Net Income/Loss:
$-24.73M
P/E Ratio:
-0.3204
EPS:
-4.213
Net Cash Flow:
$-20.36M
1W Performance:
-3.57%
1M Performance:
-2.88%
6M Performance:
-79.73%
1Y Performance:
-90.07%
1-Day Range:
$1.34
$1.53
1-Week Range:
$1.24
$1.53
52-Week Range:
$1.17
$16.00
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
1.35 | 16.09M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
527.05 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.05 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.57 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.95 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
134.29 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | H.C. Wainwright | Buy |
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRX (VNRX) Registration filing Summary - Quartr
VNRX Announces Sale of 3.31 Million Shares by Selling Stockholders - GuruFocus
VolitionRx (NYSE: VNRX) files to register 3.3M Lind-linked shares for resale - Stock Titan
Maxim Group Maintains VolitionRX(VNRX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
VolitionRx Ltd explores blood-based cancer diagnostics as investors watch VNRX - ad-hoc-news.de
VolitionRx releases lung cancer prognostic study data - Investing.com
VolitionRx releases lung cancer prognostic study data By Investing.com - Investing.com Australia
VolitionRx’s lung cancer test could help doctors predict outcomes - Stock Titan
VolitionRx prices $4.6 million public offering at $1.55 per share By Investing.com - Investing.com UK
VolitionRX Ltd (VNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VolitionRX Ltd Actuals & Estimates (AMEX:VNRX) - TradingView
VolitionRX Ltd (VNRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VolitionRX Ltd (VNRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VNRX Forecast — Price Target — Prediction for 2027 - TradingView
VolitionRX Ltd (VNRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
What Sysmex (TSE:6869)'s Nu.Q NETs Collaboration With VolitionRx Means For Shareholders - simplywall.st
VolitionRX Ltd (VNRX) Institutional Confidence - TradingKey
VOLITIONRX ANNOUNCES PRICING OF $4.6 MILLION PUBLIC OFFERING - Moomoo
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VNRX Reinstated by Maxim Group -- Price Target Announced at $4.0 - GuruFocus
VolitionRx Limited 8-K Filing: Key Corporate Details and SEC Registration for June 2026 - Minichart
VolitionRx (NYSE: VNRX) issues stock to Lind for note repayments - Stock Titan
VolitionRx (VNRX) Receives Buy Rating with $4 Price Target from Maxim - GuruFocus
VolitionRX Ltd (VNRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VolitionRX Ltd (VNRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VolitionRX Ltd (VNRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VolitionRx Limited (VNRX) Partners with Sysmex to Enhance Diagno - GuruFocus
Sysmex (TSE:6869) Stock Could Be 17.8% Undervalued After VolitionRx Collaboration - simplywall.st
VolitionRx (VNRX) Forms Partnership with Sysmex for Assay Optimi - GuruFocus
VolitionRx partners with Sysmex on diagnostic test development By Investing.com - Investing.com Nigeria
VolitionRx partners with Sysmex on diagnostic test development - Investing.com
VolitionRx partners with Sysmex to optimize NETs test for sepsis and other diseases - Stock Titan
VolitionRx Ltd Stock (US92852X1037): Quarterly earnings keep early-detection biotech in focus - Ad-hoc-news.de
VolitionRx Enters Securities Purchase Agreement With Investors to Raise Capital - TradingView
VolitionRx (NYSE: VNRX) prices $4.6M stock offering with $2.3M warrant upside - Stock Titan
VolitionRx (NYSE: VNRX) to Offer 2.96M Shares and 1.48M Warrants - Stock Titan
VolitionRx stock tumbles on $4.6M offering priced at discount By Investing.com - Investing.com Nigeria
VolitionRx prices $4.6 million public offering at $1.55 per share - Investing.com
VolitionRx Announces Pricing of $4.6 Million Public Offering - marketscreener.com
Epigenetics firm VolitionRx prices $4.6M deal with $2.3M in potential warrant proceeds - Stock Titan
VolitionRx (VNRX) files shelf prospectus for stock, detachable warrants - Stock Titan
H.C. Wainwright cuts VolitionRX stock price target to $1 on share count - Investing.com
VNRX Technical Analysis & Stock Price Forecast - Intellectia AI
New Ebola triage blood test: VolitionRx seeks partners for outbreak zones - Stock Titan
VolitionRx (NYSE: VNRX) seeks approval to cut authorized shares and add 2026 stock plan - Stock Titan
Benchmark reiterates Hold on VolitionRX stock amid milestones By Investing.com - Investing.com South Africa
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):